Conditioning with Î±-emitter based radioimmunotherapy in canine allogeneic hematopoietic cell transplantation.
Chimerism., 3(2):40-2 (2012 Apr-Jun)
Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS.
Blood., Aug;120(7):1398-408 (2012)
Efficacy of a viral load-based, risk-adapted, preemptive treatment strategy for prevention of cytomegalovirus disease after hematopoietic cell transplantation.
Biol. Blood Marrow Transplant., Nov;18(11):1687-99 (2012)
Reagents for astatination of biomolecules. 6. An intact antibody conjugated with a maleimido-closo-decaborate(2-) reagent via sulfhydryl groups had considerably higher kidney concentrations than the same antibody conjugated with an isothiocyanato-closo-de
Bioconjug. Chem., Mar;23(3):409-20 (2012)
The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation.
Blood., Mar;119(11):2657-64 (2012)
A limited sampling schedule to estimate mycophenolic Acid area under the concentration-time curve in hematopoietic cell transplantation recipients.
J Clin Pharmacol., Nov;52(11):1654-64 (2012)
Reduced-intensity conditioning in allogeneic stem cell transplantation for hematological malignancies: a historical perspective.
Onkologie., 34(12):710-5 (2011)
Nonmalignant late effects and compromised functional status in survivors of hematopoietic cell transplantation.
J. Clin. Oncol., Jan;30(1):71-7 (2012)
Durable donor engraftment after radioimmunotherapy using Î±-emitter astatine-211-labeled anti-CD45 antibody for conditioning in allogeneic hematopoietic cell transplantation.
Blood., Feb;119(5):1130-8 (2012)
Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies.
JAMA., Nov;306(17):1874-83 (2011)
Prognostic impact of discordant results from cytogenetics and flow cytometry in patients with acute myeloid leukemia undergoing hematopoietic cell transplantation.
Cancer., May;118(9):2411-9 (2012)
Cytopenias after day 28 in allogeneic hematopoietic cell transplantation: impact of recipient/donor factors, transplant conditions and myelotoxic drugs.
Haematologica., Dec;96(12):1838-45 (2011)
Association between calcineurin inhibitor blood concentrations and outcomes after allogeneic hematopoietic cell transplantation.
Biol. Blood Marrow Transplant., Mar;18(3):414-22 (2012)
Immunomodulatory effects induced by cytotoxic T lymphocyte antigen 4 immunoglobulin with donor peripheral blood mononuclear cell infusion in canine major histocompatibility complex-haplo-identical non-myeloablative hematopoietic cell transplantation.
Cytotherapy., Nov;13(10):1269-80 (2011)
Decreased serum albumin as a biomarker for severe acute graft-versus-host disease after reduced-intensity allogeneic hematopoietic cell transplantation.
Biol. Blood Marrow Transplant., Nov;17(11):1594-601 (2011)
Outcome of patients with acute myeloid leukemia with monosomal karyotype who undergo hematopoietic cell transplantation.
Blood., Aug;118(6):1490-4 (2011)
Histology and time to progression predict survival for lymphoma recurring after reduced-intensity conditioning and allogeneic hematopoietic cell transplantation.
Biol. Blood Marrow Transplant., Oct;17(10):1537-45 (2011)
Non-myeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment of high-risk acute lymphoblastic leukemia.
Haematologica., Aug;96(8):1113-20 (2011)
Allogeneic hematopoietic cell transplantation for renal cell carcinoma: ten years after.
Expert Opin Biol Ther., Jun;11(6):763-73 (2011)
Allogeneic haematopoietic cell transplantation for myelofibrosis in 30 patients 60-78 years of age.
Br. J. Haematol., Apr;153(1):76-82 (2011)